Data for Roche, BMS melanoma drugs stir excitement at ASCO
This article was originally published in Scrip
Executive Summary
The promise of two new drugs in extending the lives of patients with metastatic melanoma – the deadliest form of skin cancer – was part of the big buzz in Chicago at this year's annual meeting of the American Society of Clinical Oncology (ASCO), which got underway 3 June, ending 7 June.